FIG 5.
In vivo efficacy of norharmane-polymyxin B in a mouse lung P. aeruginosa C218 infection model. (a) Scheme of the experimental protocol for the mouse lung P. aeruginosa infection model. (b) Synergism between norharmane and polymyxin B was evaluated in a mouse lung P. aeruginosa C218 infection model. At 36 h after treatment, the mice were euthanized, and their infected lungs were aseptically excised. The bacterial loads (Log10 CFU of P. aeruginosa C218) in the lung were counted. The mean ± SD for each experimental group is shown. (c–d) Evaluation of nephrotoxicity and hepatotoxicity. Cre (creatine) and ALT (alanine aminotransferase) were analyzed. The mean ± SD for each experimental group is shown. P values were determined using an unpaired, two-tailed Student's t test; ns, P > 0.05 versus the control; **, P < 0.01 versus the control; ***, P < 0.001 versus the control; ****, P < 0.0001 versus the control.